# SERF1A

## Overview
The SERF1A gene encodes the small EDRK-rich factor 1A protein, which is a key player in protein aggregation processes within human cells. This protein is characterized by its high helical propensity and predominantly monomeric nature, adopting a helix-loop-helix conformation. SERF1A is intrinsically disordered and functions as an RNA-binding and organizing protein, despite lacking traditional RNA-binding motifs. It is notably involved in the acceleration of amyloid fibrillization, interacting with amyloidogenic proteins such as amyloid-beta, α-synuclein, and huntingtin exon 1, thereby influencing neurodegenerative disease mechanisms (Tsai2023Amyloid; meinen2020serf). The gene is ubiquitously expressed in the central nervous system and has been implicated in conditions like Huntington's disease and spinal muscular atrophy, where it modulates protein aggregation and stability (Tsai2023Amyloid; Brkušanin2015Joint).

## Structure
The SERF1A protein is characterized by a high helical propensity, with its secondary structure predominantly consisting of α-helices and loops. Specifically, it adopts a helix-loop-helix conformation, with 66% of its structure being α-helices and 34% loops (Tsai2023Amyloid). The protein's secondary structure includes two helices, spanning residues E8 to Q12 and A33 to A51, connected by a long loop (Tsai2023Amyloid). 

In terms of tertiary structure, SERF1A is described as having a relatively elongated conformation with converged helical features, although there is some variability in local non-rigid segments (Lin2024Binding). The protein is predominantly monomeric, as shown by analytical ultracentrifugation (Tsai2023Amyloid). 

SERF1A interacts with amyloid-beta and α-synuclein, enhancing their fibrillization, and it also accelerates the fibril formation of huntingtin exon 1 in a polyQ length-dependent manner (Tsai2023Amyloid). The protein is enriched in lysine and arginine and is known to promote amyloid formation in vitro (Tsai2023Amyloid). SERF1A has two isoforms, a short form with 62 residues and a long form with 110 amino acids, both ubiquitously expressed in the central nervous system (Tsai2023Amyloid).

## Function
SERF1A is a protein that plays a significant role in amyloid formation and protein homeostasis within human cells. It is involved in the acceleration of amyloid fibrillization, particularly interacting with amyloidogenic proteins such as α-synuclein and amyloid-beta (Aβ), enhancing their fibril formation in vitro (Tsai2023Amyloid; meinen2020serf). SERF1A is intrinsically disordered and has been identified as an RNA-binding and organizing protein, although it lacks traditional RNA-binding motifs (meinen2020serf). This suggests a potential role in RNA regulation, which may be linked to its function in amyloid formation.

In the context of Huntington's disease, SERF1A interacts with polyglutamine-expanded huntingtin-exon 1 (Httex1), promoting its aggregation and exacerbating polyQ-induced toxicity. This interaction is primarily mediated through the N-terminal 17 residues of Httex1, facilitating a conformational transition to β-sheet-rich structures (Tsai2023Amyloid). SERF1A is ubiquitously expressed in the central nervous system and is active in the cytoplasm, where it influences protein aggregation processes that are crucial for maintaining cellular function (Tsai2023Amyloid). Its role in modulating protein misfolding and aggregation pathways highlights its potential impact on neurodegenerative disease mechanisms.

## Clinical Significance
The SERF1A gene is implicated in several neurodegenerative and neuromuscular diseases due to its role in protein aggregation. In Huntington's disease (HD), SERF1A interacts with the polyglutamine-expanded huntingtin-exon 1 (Httex1), exacerbating polyQ-induced toxicity. This interaction accelerates the transition of mutant Httex1 to a toxic β-sheet conformation, promoting aggregation and increasing cytotoxicity in neuronal cells. Elevated levels of SERF1A have been observed in HD models, including transgenic mice and human HD iPSCs, suggesting its detrimental role in HD pathology (Tsai2023Amyloid).

In spinal muscular atrophy (SMA), SERF1A is considered a genetic modifier. Its copy number variations correlate with the severity of SMA, with deletions frequently observed in type I SMA patients. The gene's proximity to the SMN locus and its potential role in protein aggregation suggest it may influence SMA phenotypes by modulating protein stability and aggregation (Zhuri2022Investigation; Brkušanin2015Joint). Despite its involvement in these conditions, the exact mechanisms by which SERF1A contributes to disease pathogenesis remain to be fully elucidated.

## Interactions
SERF1A is known to interact with several proteins, playing a significant role in protein aggregation processes. It interacts with polyglutamine-expanded huntingtin-exon 1 (Httex1), particularly through its N-terminal 17 residues (NT17), facilitating the conversion of monomeric conformers to β-sheet-rich species, which accelerates fibril formation. This interaction is characterized by a stoichiometry of 0.5, where one SERF1A molecule interacts with two Httex1 proteins, and is enhanced by coiled-coil interactions between the NT17 domain of Httex1 and SERF1A (Tsai2023Amyloid).

SERF1A also interacts with α-synuclein, promoting its fibrillization, and has been shown to enhance the fibril formation of amyloid-beta (Aβ) and prion proteins (Tsai2023Amyloid). The protein's interaction with these amyloidogenic proteins suggests a role in neurodegenerative diseases by promoting protein aggregation rather than preventing it (Tsai2023Amyloid).

In addition to protein interactions, SERF1A is identified as an RNA-organizing protein, forming complexes with RNA. This interaction leads to its inability to distinguish between nucleic acids and amyloid proteins, indicating a broader role in cellular processes involving nucleic acids (Tsai2023Amyloid).


## References


[1. (Zhuri2022Investigation) Drenushe Zhuri, Hakan Gurkan, Damla Eker, Yasemin Karal, Sinem Yalcintepe, Engin Atli, Selma Demir, and Emine Ikbal Atli. Investigation on the effects of modifying genes on the spinal muscular atrophy phenotype. Global Medical Genetics, 09(03):226–236, September 2022. URL: http://dx.doi.org/10.1055/s-0042-1751302, doi:10.1055/s-0042-1751302. This article has 5 citations.](https://doi.org/10.1055/s-0042-1751302)

[2. (Lin2024Binding) Tien-Chang Lin, Orion Shih, Tien-Ying Tsai, Yi-Qi Yeh, Kuei-Fen Liao, Bradley W. Mansel, Ying-Jen Shiu, Chi-Fon Chang, An-Chung Su, Yun-Ru Chen, and U-Ser Jeng. Binding structures of serf1a with nt17-polyq peptides of huntingtin exon 1 revealed by sec-swaxs, nmr and molecular simulation. IUCrJ, 11(5):849–858, August 2024. URL: http://dx.doi.org/10.1107/s2052252524006341, doi:10.1107/s2052252524006341. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1107/s2052252524006341)

[3. (Tsai2023Amyloid) Tien-Ying Tsai, Chun-Yu Chen, Tien-Wei Lin, Tien-Chang Lin, Feng-Lan Chiu, Orion Shih, Ming-Yun Chang, Yu-Chun Lin, An-Chung Su, Chiung-Mei Chen, U-Ser Jeng, Hung-Chih Kuo, Chi-Fon Chang, and Yun-Ru Chen. Amyloid modifier serf1a interacts with polyq-expanded huntingtin-exon 1 via helical interactions and exacerbates polyq-induced toxicity. Communications Biology, July 2023. URL: http://dx.doi.org/10.1038/s42003-023-05142-0, doi:10.1038/s42003-023-05142-0. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-023-05142-0)

[4. (Brkušanin2015Joint) Miloš Brkušanin, Ana Kosać, Vladimir Jovanović, Jovan Pešović, Goran Brajušković, Nikola Dimitrijević, Slobodanka Todorović, Stanka Romac, Vedrana Milić Rašić, and Dušanka Savić-Pavićević. Joint effect of the smn2 and serf1a genes on childhood-onset types of spinal muscular atrophy in serbian patients. Journal of Human Genetics, 60(11):723–728, August 2015. URL: http://dx.doi.org/10.1038/jhg.2015.104, doi:10.1038/jhg.2015.104. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/jhg.2015.104)

5. (meinen2020serf) SERF is a modifier of amyloid formation. This article has 0 citations.